List of Devices Companies in Israel - 24

3NT Medical is taking ENT endoscopy further, with a family of novel maneuverable, single-use endoscopes purpose-built for the unique needs of ENT specialists.

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases. The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on two directions: treatment of acute ischemic stroke, and chronic SPG stimulation to treat vascular dementia patients.

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect precancerous polyps and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. Please view our notice Terms of Use here: https://check-cap.com/terms-of-use/

We designed a portable, affordable and easy to use hematology lab, which provides instant results like CBC, complete blood count. The platform technology houses multiple clinical applications and has an AI based microscope. It reduces cost, time and it improves the doctor-patient experience. EFA brings the LAB to the BLOOD and not the BLOOD to the LAB without the need for an expert preparation. EfA is changing the diagnostics paradigm step by step by enabling tests which were ONLY available in the labs/clinics/hospitals etc. to be done ANYTIME and EVERYWHERE. An early and rapid diagnostic is a key to the prevention of overuse and improper medications. Many millions of people cannot access a proper diagnostic due to their medical condition and/or where they live. Bringing as many as possible medical services closer to them, will make a huge impact on how we manage health around the world. The initial application of a complete blood count everywhere will give results in less than 5 minutes ON THE DEVICE. EfA also creates a marketplace for developers, partners and researches adding health-apps for various conditions and future diagnostic needs. EfA's RevDx portable device realtime analysis enables telemedicine applications.

Eitan Medical is reimagining drug delivery with reliable innovation that puts patients at the center of care, making infusion easier and safer than ever before. Patient safety and care is only the starting point, as Eitan Medical goes beyond, delivering connected, intuitive infusion solutions that are designed to improve patients' and clinicians' quality of life across the continuum of care, including hospital, ambulatory care, and home care solutions. For over a decade, Eitan Medical and its global partners have provided safe, intuitive, and flexible infusion solutions that meet evolving drug delivery needs.

Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patient's hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.

Healium Medical is focused on advancing atrial fibrillation treatment with an innovative no-contact guided ablation technology allowing simultenuous tissue ablation and lesion monitoring. The company operates out of Alon Medtech Ventures (http://www.alon-medtech.com) in Yokneam, Israel, and have demonstrated its proof-of-concept in an animal model. EP Physicians interested to collaborate, contibute to product defintnion and experience the technology first-hand are welcome to contact us.

INSIGHTEC Ltd. is a global healthcare company that specializes in creating the next generation of patient care by harnessing the therapeutic power of acoustic energy. The company was founded in 1999 by GE Healthcare and Elbit Medical Imaging to bring MRI-guided focused ultrasound technology to the market. INSIGHTEC's technology uses sound waves to precisely target and ablate tissue with no incisions, minimal risk of infection, and often allows patients to undergo treatment on an outpatient basis.

INTEC PHARMA is a pharmaceutical distribution company that specializes in cold chain logistics for healthcare products.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

Limaca Medical Ltd, is a privately held company dedicated to improving endoscopic biopsy results for patients facing potentially life-threatening gastroenterology and pulmonary cancers. Limaca's experienced team of engineers, clinicians, and business professionals have track records of innovating, developing, and commercializing specialized medical devices. Limaca Medical was founded in 2017 in cooperation with Rambam Health Care, a leading Israeli medical center, and The Trendlines Group in collaboration with the Israel Innovation Authority.

Lumenis creates and commercializes innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. We have successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Lumenis has a rich history of defying technological boundaries, redefining standards within our domains, and transforming people's lives - both inside and out. Our drive for innovation stems from an uncompromising commitment to providing best-in-class technologies and solutions designed to achieve excellent results. Lumenis has a solid global footprint in developed and emerging markets and sales in over 100 countries. Headquartered in Israel and with offices on four continents, our team consists of nearly 1,500 professionals worldwide.

Magenta is developing miniaturized catheter-mounted axial flow-pumps for mechanical circulatory support indications, based on Magenta's core technology of self-expanding impellers and pump heads. Our percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.

Neurotrigger develops the next generation wearable powered muscle re-education stimulation system. Re-educating muscles is important for facilitating and improving muscle performance and muscle's range of motion, and for the prevention or retardation of disuse atrophy.

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.

Oxitone is a leading wearables and digital health company helping providers deliver continuous remote care for people with severe chronic and complex conditions and ensure the best clinical outcomes. MAXIMIZE VALUE AT LOW COST The top 5% of people with severe chronic conditions account for 50% of care spending. Practicing fragmented care doesn't deliver help in time. Oxitone generates continuous remote measurements of multiple physiological parameters and their derivatives, so any critical deviations could be flagged and notified in a timely manner. Oxitone continuous monitoring solution helps to maximize care for patients while significantly reduce cost. VitalsTone™ AI-POWERED ANALYTICS ENGINE At the core of Oxitone is the VitalsTone™ exceptionally accurate personalized data analytics engine integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. It passively collects and analyses multiple critical physiological parameters and their derivatives (hospital-grade) in real time and guides personalized therapeutic decision-making ULNAR BONE FlexSense™ CONTINUOUS MONITORING TECHNOLOGY Oxitone 1000M is the first FDA-cleared wrist medical monitor that works without a bulky fingertip probe. Oxitone's elastics sensors gently embrace wrist ulnar bone, do not affect local blood flow and provide superior accuracy, comfort and monitoring continuity. The technology was intensively validated through FDA clearance and numerous clinical applications. Oxitone is spotlighted on The New York Times, MobiHealthNews, MedCityNews, and Digital Health Global 100. Won awards from Cleveland Clinic, NODE.Health, Tech Tour, and Hello Tomorrow. Oxitone was a part of StartUp Health and TEDMED Hive 2014.

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.

TechnoPulm introduces a disruptive diagnostic tool for Pulmonary-Function Testing (PFT) in patients suffering from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, covid related ailments and others. TechnoPulm is the only company that has systems that allows ALL lung function diagnostic tests to be performed from the doctor's office and the patient's home by using a small handheld device connected to a comprehensive tool to enable a remote healthcare solution. TechnoPulm enables patients to interact with their physician from anywhere at any time.

Vensica Medical is a medical device company that is designing and developing and Ultrasound catheter for the treatment of bladder cancer. Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica's device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.

Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.